SEIKAGAKU CORPORATION
4548・Prime Market・Pharmaceuticals
Business
Seikagaku Corporation, founded in 1947, is a Tokyo Stock Exchange Prime Market-listed pharmaceutical company specializing in carbohydrate science (glycosaminoglycans, etc.). It operates two segments: the Pharmaceuticals Business, comprising joint function improving agents, ophthalmic surgery aids, lumbar disc herniation treatments, and others; and the LAL Business, comprising Endotoxin Assay Reagent and Glucan Assay In Vitro Diagnostic Reagent for pharmaceutical quality control. The company has entered into sales partnerships with pharmaceutical and medical device companies both in Japan and overseas, adopting a fabless model in which it concentrates its management resources on R&D and manufacturing. In Japan, it has partnered with Kaken Pharmaceutical, Santen Pharmaceutical, Ono Pharmaceutical, and others, while overseas it has partnered with Zimmer Biomet, Bioventus, and others, conducting business globally with a focus on Japan, the U.S., and China.
Business Model
In the Pharmaceuticals Business, the company does not maintain its own sales department; instead, it grants exclusive distribution rights to leading companies in Japan and overseas, earning product supply consideration, royalties, and milestone income. In the LAL Business, subsidiary Associates of Cape Cod, Inc. handles manufacturing and sales, capturing demand for quality control in pharmaceutical manufacturing processes. R&D expenses remain at a high level, accounting for 19.1% of net sales (FY2026, ending March 2026), reflecting a structure that continuously generates new products from the company's foundational carbohydrate science technologies.
Company Strengths
Joint Function Improving Agent ARTZ and Ophthalmic Surgery Aid Opegan Series each maintain the top share in their respective domestic markets. A stable supply system has been established based on long-term sales partnership agreements with Kaken Pharmaceutical, Santen Pharmaceutical, and others, and sales to Kaken Pharmaceutical in FY2026 (ending March 2026) reached ¥9,643 million (26.3% of the total).
The company possesses foundational technology related to glycosaminoglycans (hyaluronic acid, chondroitin sulfate, etc.) and applies it across multiple disease areas including joints, ophthalmology, intervertebral discs, anti-adhesion, and cystitis. R&D personnel account for 18.7% (214 employees) of total employees, and the company continues to invest ¥7,010 million in R&D expenses (19.1% of net sales).
The LAL Business, centered on subsidiary Associates of Cape Cod, Inc., continued stable growth with sales of ¥12,152 million in FY2026 (ending March 2026) (up 2.5% year on year). Through market penetration of the recombinant Endotoxin Assay Reagent PyroSmart NextGen and expansion into more countries for the Glucan Assay In Vitro Diagnostic Reagent, the business is strengthening its foundation through both legacy and next-generation products.
ENVALITH's Perspective
Performance Trend
Revenue for FY2026 (ending March 2026) was ¥36,645 million (down 6.9% year on year), and the company posted an operating loss of ¥660 million, falling into the red from operating income of ¥1,333 million in the previous fiscal year. The main causes were a 99.9% year-on-year decrease in royalty income (from ¥2,598 million to ¥1 million) and a decline in Supartz FX for the U.S. market (overseas pharmaceuticals down 4.4%). Meanwhile, the LAL Business remained solid, growing 2.5%. In non-operating income, gain on sale of investment securities of ¥1,261 million and foreign exchange gain of ¥354 million were recorded, securing ordinary income of ¥1,679 million. Due to a review of deferred tax assets, net income for the period was ¥1,473 million (up 21.3% year on year). The numerical targets of the medium-term management plan (FY2023 (ending March 2023) through FY2026 (ending March 2026)) — revenue of ¥40.0 billion and operating income of ¥7.0 billion — were ultimately not achieved. External factors, such as a shift toward reduced-frequency dosing products in the U.S. and the expansion of centralized procurement systems in China, have created headwinds for overseas pharmaceuticals.
Growth Strategy
Aiming for sustainable growth through three pillars: SI-6603 U.S. approval, progress on new pipeline products, and expansion of the LAL Business
Resubmitted the biologics license application to the FDA in March 2026. No concerns regarding efficacy or safety were raised, and the resubmission followed the completion of responses to additional comments concerning manufacturing facility, drug substance, and formulation controls. If approval and launch are achieved, a fundamental improvement in the earnings structure is expected as royalty income moves into full swing.
Applied for domestic marketing authorization for the medical device in August 2025 and obtained approval in April 2026. This powder-form medical device, whose main component is cross-linked chondroitin sulfate, offers excellent handling in laparoscopic surgery. Following the domestic launch, global expansion is also being considered, and the creation of a new revenue source is expected.
Signed a formal agreement in August 2025 with Ono Pharmaceutical Co., Ltd. for co-development and sales partnership. Domestic Phase III clinical trials are underway for knee osteoarthritis and hip osteoarthritis. A single-dose pain-suppressing effect has been confirmed in U.S. clinical trials, and following domestic approval, the company aims to commercialize the product leveraging Ono Pharmaceutical's sales network.
Promoting market penetration of the recombinant Endotoxin Assay Reagent 'PyroSmart NextGen' and expanding the number of countries where the Glucan Assay In Vitro Diagnostic Reagent is sold, as well as developing new hospital markets. LAL Business net sales for FY2026 (ending March 2026) continued to grow steadily at ¥12,152 million (up 2.5% year on year), and further expansion is expected in FY2027 (ending March 2027).
Promoting capital investment at the overseas subsidiary Dalton Chemical Laboratories Inc. (Toronto, Canada) and the transfer of manufacturing technology from Japan. Establishing a two-site production system together with the Takahagi Plant (Ibaraki Prefecture) to strengthen the stable supply framework. Capital expenditures on property, plant and equipment for FY2026 (ending March 2026) increased significantly to ¥5,900 million from ¥4,389 million in the previous fiscal year, indicating that the investment phase continues.
Last updated: July 19, 2026